1. Signaling Pathways
  2. GPCR/G Protein
  3. Ras
  4. K-Ras Isoform
  5. K-Ras Inhibitor

K-Ras Inhibitor

K-Ras Inhibitors (106):

Cat. No. Product Name Effect Purity
  • HY-114277
    Inhibitor 99.94%
    Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor.
  • HY-130149
    Inhibitor 99.93%
    Adagrasib (MRTX849) is a potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C with potential antineoplastic activity.
  • HY-134813
    Inhibitor 99.42%
    MRTX1133 is a noncovalent, potent, and selective KRAS G12D inhibitor.
  • HY-126247
    Inhibitor 98.74%
    BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based drug design with nanomolar affinity.
  • HY-125817
    Inhibitor 99.95%
    BI-3406 (compound I-6) is an orally active, highly potent and selective inhibitor of the interaction between KRAS and Son of Sevenless 1 (SOS1) with an IC50 of 6 nM.
  • HY-122914
    KRAS inhibitor-3
    Inhibitor 99.65%
    KRAS inhibitor-3 is an inhibitor of KRAS inhibitor.
  • HY-151881
    SOS1-IN-15 (Compound 37) is an orally active SOS1 inhibitor with an IC50 of 5 nM.
  • HY-153346
    RMC-6291 is an orally active and covalent inhibitor of KRASG12C(ON).
  • HY-114398
    Inhibitor 98.06%
    BAY-293, a valuable chemical probe, blocks RAS activation via disruption of the KRAS-SOS1 interaction with an IC50 of 21 nM.
  • HY-137516
    LC-2 is a potent and first-in-class von Hippel-Lindau-based PROTAC capable of degrading endogenous KRAS G12C, with DC50s between 0.25 and 0.76 μM.
  • HY-U00418
    Inhibitor 98.80%
    ARS-1620 is an atropisomeric selective KRASG12C inhibitor with desirable pharmacokinetics.
  • HY-114436
    Inhibitor 99.14%
    MRTX-1257 is a selective, irreversible, covalent and orally active KRAS G12C inhibitor, with an IC50 of 900 pM for KRAS dependent ERK phosphorylation in H358 cells.
  • HY-139612
    Inhibitor 98.94%
    Opnurasib (JDQ-443) (NVP-JDQ443) is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1).
  • HY-145926
    Inhibitor 99.45%
    MRTX0902 is an orally active and potent SOS1 inhibitor with an IC50 of 46 nM (WO2021127429A1; Example 12-10).
  • HY-129523
    PROTAC K-Ras Degrader-1
    Inhibitor 98.05%
    PROTAC K-Ras Degrader-1 (Compound 518) is a PROTAC.
  • HY-114277A
    Sotorasib racemate
    Inhibitor 98.99%
    Sotorasib (AMG-510) racemate is the racemate of Sotorasib (AMG-510).
  • HY-145928
    Inhibitor 99.46%
    Divarasib (GDC-6036) is an orally bioavailable, highly potent, and selective KRAS G12C inhibitor with an IC50 of <0.01 μM.
  • HY-141477
    Inhibitor 98.03%
    RM-018 is a potent, functionally distinct tricomplex KRASG12C active-state inhibitor.
  • HY-19706
    Inhibitor 98.39%
    ARS-853 is a cell-active, selective, covalent KRAS G12C inhibitor with an IC50 of 2.5 μM.
  • HY-128522
    Inhibitor 99.59%
    ARS-1323-alkyne, a switch-II pocket (S-IIP) inhibitor, is a conformational specific chemical reporter of KRASG12C nucleotide state in living cells.